Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
$33.99
$33.89
$17.00
$39.30
$1.63B2.59940,325 shsN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$28.09
-3.0%
$27.71
$17.82
$30.69
$2.05B0.05556,024 shs355,269 shs
Omeros Corporation stock logo
OMER
Omeros
$3.65
+5.5%
$3.73
$2.95
$13.60
$213.85M2.16735,882 shs954,253 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.41
+0.7%
$1.38
$1.10
$16.10
$86.56M1.31.20 million shs581,363 shs
Zogenix, Inc. stock logo
ZGNX
Zogenix
$26.68
$26.52
$11.03
$26.90
$1.50B0.893.76 million shs94 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+0.52%+3.93%-2.75%+49.92%+38.12%
Omeros Corporation stock logo
OMER
Omeros
+2.37%+8.09%-10.82%-48.59%-14.57%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+2.94%+12.45%-9.09%+4.48%-87.38%
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.5926 of 5 stars
3.54.00.00.02.93.30.6
Omeros Corporation stock logo
OMER
Omeros
3.294 of 5 stars
3.40.00.04.40.01.70.6
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
4.5169 of 5 stars
3.05.00.04.73.21.70.6
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
0.00
N/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$39.3340.03% Upside
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00393.15% Upside
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$13.31844.15% Upside
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CNST, KNSA, OMER, ZGNX, and PLRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.00
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/29/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $45.00
4/16/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
4/11/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/A$8.63 per shareN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$423.24M4.84N/AN/A$6.60 per share4.26
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M54.78N/AN/A$5.00 per share0.28
Zogenix, Inc. stock logo
ZGNX
Zogenix
$81.69M18.36N/AN/A$6.64 per share4.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M-$0.25N/A112.36N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)
Zogenix, Inc. stock logo
ZGNX
Zogenix
-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/A

Latest CNST, KNSA, OMER, ZGNX, and PLRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.62N/AN/AN/AN/AN/A
7/22/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.08N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
4/29/2025Q1 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.02$0.11+$0.09$0.11$128.35 million$137.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/A
15.39
15.39
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.66
3.43
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
11.03
11.03
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.88
3.63
4.74
CompanyEmployeesShares OutstandingFree FloatOptionable
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
15447.92 millionN/ANot Optionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22072.97 million33.95 millionOptionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.48 millionOptionable
Zogenix, Inc. stock logo
ZGNX
Zogenix
21856.23 million53.92 millionOptionable

Recent News About These Companies

Hwasung Industrial Co Ltd 002460
Orally Inhaled Dihydroergotamine
MRI in Headache
Kratom: What We Know
Alcon (NYSE: ALC)
Longeveron Inc Ordinary Shares - Class A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Constellation Pharmaceuticals stock logo

Constellation Pharmaceuticals NASDAQ:CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.09 -0.86 (-2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$28.23 +0.14 (+0.51%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Omeros stock logo

Omeros NASDAQ:OMER

$3.65 +0.19 (+5.49%)
Closing price 04:00 PM Eastern
Extended Trading
$3.68 +0.04 (+0.96%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.41 +0.01 (+0.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 -0.04 (-3.19%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zogenix stock logo

Zogenix NASDAQ:ZGNX

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.